

Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals, New Delhi - A Joint Sector Venture of Govt. of Delhi)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi-110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phones : 91-11-26925858, 26925801, Fax : 91-11-26823629

E-mail : imcl@apollohospitals.com, Website : <https://delhi.apollohospitals.com>

Ref: IMCL/CS/BM/2023

23rd May, 2023

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Re: Outcome of the Board Meeting held on 23rd May, 2023

Dear Sir,

This is to inform that the Board of Directors of the Company has, at its meeting held on Tuesday, 23rd May, 2023 (i.e. today), inter-alia :

1. Approved the Audited Financial Statements for the year ended 31st March, 2023 and Audited Financial Results for the quarter/year ended 31st March, 2023, as recommended by the Audit Committee; and
2. Recommended a dividend @ 30% i.e. Rs. 3.00 per share for the financial year 2022-23.

Pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- i) Audited Financial Results for the quarter/year ended 31st March, 2023;
- ii) Auditors' Report with unmodified opinion on the aforesaid Audited Financial Results; and
- iii) Declaration by CFO confirming that the Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year ended 31st March 2023.

The meeting of the Board of Directors commenced at 3.00 p.m. and concluded at 5:00 p.m.

We shall inform you in due course of time, the date on which the Company will hold its Annual General Meeting for the year ended 31st March, 2023, and the date from which dividend, if approved by the shareholders, will be paid or warrants thereof dispatched to the shareholders.

This is for your information and record.

Thanking You,

Yours sincerely,

For Indraprastha Medical Corporation Limited



Priya Ranjan

AVP - Corporate Affairs & Legal

(Company Secretary & Compliance Officer)

Independent Auditor's Report**To the Board of Directors of Indraprastha Medical Corporation Limited****Report on the Audit of Financial Results****Opinion**

We have audited the Financial Results of **Indraprastha Medical Corporation Limited** ("the Company") for the year ended 31 March, 2023 included in the accompanying Statement of 'Financial Results for the quarter and year ended 31 March, 2023' ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:


- i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India, of the net profit and total comprehensive income and other financial information of the Company for the year ended 31 March, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Statement

This Statement has been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these Financial Results that give a true and fair view of the net profit and total comprehensive income and other financial information of the Company in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate



accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Statement

Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole, are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit



evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Financial Results include the results for the quarter ended 31 March, 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **S.N. Dhawan & CO LLP**

Chartered Accountants

Firm Registration No.: 000050N/N500045



Rajeev K Saxena

Partner

Membership No.: 077974

UDIN: 23077974BGXFFC7330

Place: New Delhi

Date: 23 May, 2023

Statement of audited Financial Results for the Quarter and Year ended 31st March, 2023

Amount (Rs. in crore)


S. No.	Particulars	Quarter ended			Year ended	
		31.03.2023 (Refer Note 6)	31.12.2022 (Unaudited)	31.03.2022 (Refer Note 6)	31.03.2023 (Audited)	31.03.2022 (Audited)
1	Revenue from operations	274.05	276.93	215.74	1098.67	888.16
2	Other Income	4.79	3.08	1.81	10.03	3.12
3	Total income	278.84	280.01	217.55	1108.70	891.28
4	Expenses					
	a) Cost of material consumed	47.28	46.23	37.06	193.61	173.72
	b) Employee benefits expense	65.38	64.80	49.51	246.70	213.92
	c) Professional charges to doctors	69.32	70.15	54.60	280.55	209.52
	d) Finance cost	0.87	0.87	0.72	4.28	3.41
	e) Depreciation and amortisation expense	9.86	9.86	8.64	39.27	34.94
	f) Other expenses	58.93	58.69	47.05	227.11	176.70
	Total expenses	251.64	250.60	197.58	991.52	812.21
5	Profit before exceptional items and tax	27.20	29.41	19.97	117.18	79.07
6	Exceptional items	-	-	-	-	-
7	Profit before tax (PBT)	27.20	29.41	19.97	117.18	79.07
8	Tax expense					
	Current tax	3.27	9.97	(0.52)	31.14	17.53
	Deferred tax	4.09	(1.46)	5.29	(0.11)	2.92
9	Profit for the period after tax (PAT)	19.84	20.90	15.20	86.15	58.62
10	Other comprehensive income					
	a). (i) Items that will not be reclassified to profit or loss	(7.76)	1.30	0.59	(12.32)	(7.92)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	1.95	(0.32)	(0.15)	3.10	1.99
	Total other comprehensive income (Net of tax expenses)	(5.81)	0.98	0.44	(9.22)	(5.93)
11	Total comprehensive income for the period	14.03	21.88	15.64	76.93	52.69
12	Paid-up equity share capital (Face value Rs. 10/- each)	91.67	91.67	91.67	91.67	91.67
13	Reserves (excluding Revaluation Reserves) as shown in the audited balance sheet of previous year				287.78	233.77
14	Earnings per share Basic and Diluted (Rs.) - Not Annualised	2.16	2.28	1.66	9.40	6.39

Signature



Statement of Assets and Liabilities:		Amount (Rs. in crore)	
		As at	
		Audited	Audited
Particulars		31.03.2023	31.03.2022
A.	ASSETS		
1	Non-current assets		
	(a) Property, Plant and Equipment	272.26	270.88
	(b) Right-of-use asset	1.83	4.27
	(c) Capital work-in-progress	2.53	-
	(c) Intangible Assets	0.96	1.71
	(d) Financial Assets	47.42	24.84
	(e) Other non-current Assets	7.06	2.58
		332.06	304.28
2	Current assets		
	(a) Inventories	8.45	9.99
	(b) Financial Assets		
	(i) Trade receivables	68.24	43.35
	(ii) Cash and cash equivalents	52.26	41.74
	(iii) Bank Balances other than (ii) above	76.49	26.71
	(iv) Other Financial Assets	6.78	5.16
	(c) Current Tax Assets (Net)	-	16.87
	(d) Other current assets	10.86	13.61
		223.08	157.43
	TOTAL OF ASSETS	555.14	461.71
B.	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share capital	91.67	91.67
	(b) Other Equity	287.78	233.77
		379.45	325.44
	Liabilities		
2	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Security Deposits	1.66	1.79
	(ii) Lease Liabilities	-	2.48
	(b) Provisions	24.42	15.31
	(c) Deferred tax liabilities (Net)	19.98	23.19
		46.06	42.77
3	Current liabilities		
	(a) Financial Liabilities		
	(i) Trade payables		
	- Total outstanding dues of micro and small enterprises	0.53	1.43
	- Total outstanding dues of creditors other than micro and small enterprises	97.65	75.32
	(ii) Lease Liabilities	2.48	2.83
	(iii) Other financial liabilities	0.76	0.73
	(b) Other current liabilities	14.30	12.32
	(c) Provisions	9.49	0.87
	(d) Current Tax Liabilities (Net)	4.42	-
		129.63	93.50
	TOTAL OF EQUITY AND LIABILITIES	555.14	461.71

Signature



Statement of Cash Flows		Amount (Rs. in crore)	
		Year ended	
Particulars		31.03.2023	31.03.2022
		(Audited)	(Audited)
A. CASH FLOW FROM OPERATING ACTIVITIES			
Profit before tax		117.18	79.07
<u>Add:</u>			
Depreciation and amortization expense		39.27	34.94
Interest expense		0.46	0.61
Loss on disposal of Assets		0.87	5.77
<u>Deduct:</u>			
Interest Income		10.03	3.12
Operating Profit before Working Capital changes		147.75	117.27
<u>Adjustments for:</u>			
Trade & Other Receivables		(23.49)	25.95
Trade payables		28.61	(28.15)
Inventories		1.54	(1.25)
Cash Generated from Operations		154.41	113.82
<u>Deduct:</u>			
Interest paid		0.09	0.01
Income tax paid		9.85	19.51
Net Cash generated from Operating Activities		144.47	94.30
B. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of Property, Plant & Equipment and Intangible Assets (Net of sale)		(44.58)	(29.48)
Movement in Other Bank Balances		(72.27)	(47.11)
Interest received		8.94	2.48
Net Cash used in Investing Activities		(107.91)	(74.11)
C. CASH FLOW FROM FINANCING ACTIVITIES			
Lease Payments		(2.83)	(2.51)
Interest paid		(0.37)	(0.60)
Dividend paid		(22.84)	(0.26)
Net Cash used in Financing Activities		(26.04)	(3.37)
Net increase / (decrease) in Cash and Cash equivalents		10.52	16.82
Opening Cash and Cash equivalents		41.74	24.92
Closing Cash and Cash equivalents		52.26	41.74
Components Cash and Cash equivalents			
Cash balance on hand		0.37	0.34
Balance with Banks		51.89	41.40

[Handwritten Signature]



Notes:

1. The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 23rd May, 2023.
2. The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
3. The Board of Directors have recommended dividend @ 30% (Rs. 3.00/- per share) for the financial year 2022-23.
4. The Directorate General of Health Services (DGHS) of Govt. of NCT Delhi, based on the recommendations of the Expert Committee of Ministry of Health and Family Welfare, Govt. of India, which was constituted in compliance of the Hon'ble Supreme Court judgment dated 29th January, 2016 in WP (C) 527/2011 in the matter of Trained Nurses Association of India Vs. Union of India & Ors, had issued an order dated 25th June, 2018, which inter-alia provides that in case of more than 200 bedded hospitals, salary given to private nurses should be at par with the salary of the nurses in the State Government hospitals. The Association of Healthcare Providers of India (AHPI) of which the Company is a member had filed a writ petition in the High Court of Delhi challenging the order issued by DGHS. The Hon'ble High Court of Delhi upheld the order dated 25th June, 2018, issued by DGHS. AHPI had filed an LPA (Letter Patent Appeal) before the division bench of the Hon'ble High Court. The division bench has admitted the LPA and the matter was sub-judice. Meanwhile, The Directorate General of Health Services (DGHS) of Govt. of NCT Delhi has withdrawn the order dated 25th June, 2018.
5. The Code on Social Security, 2020 has been enacted, which could impact the contributions by the company towards Provident Fund and Gratuity. The effective date from which the changes are applicable is yet to be notified. Impact if any, of the change will be assessed and accounted in period of notification of relevant provisions.
6. The financial results for the three months ended 31st March, 2023 and 31st March, 2022 are the balancing figures between the audited figures for the respective years ended on those dates and the unaudited year to date figures for the nine months ending 31st December, 2022 and 31st December, 2021 respectively, which were subject to limited review.
7. Previous year/period figures have been regrouped / rearranged wherever necessary.

Place : New Delhi

Date : 23rd May, 2023



A handwritten signature in blue ink, appearing to read "Shivakumar Pattabhiraman".

Shivakumar Pattabhiraman
(Managing Director)

Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals, New Delhi - A Joint Sector Venture of Govt. of Delhi)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi-110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phones : 91-11-26925858, 26925801, Fax : 91-11-26823629

E-mail : imcl@apollohospitals.com, Website : <https://delhi.apollohospitals.com>

Ref: IMCL/CS/BM/2023

23rd May, 2023

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Re: Declaration in terms of regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015

Dear Sir,

In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we confirm that the Statutory Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year 2022-23.

Thanking you,

Yours faithfully,

For Indraprastha Medical Corporation Limited

C. P. Tyagi
Chief Financial Officer